2019 Immune Response RNA Virus 
Drug Discovery World
MAY 18, 2023
This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. Moreover, some strains of influenza virus have significant pandemic potential. The trial will enrol up to 50 healthy volunteers aged 18 to 49.
The Pharma Data
JANUARY 31, 2021
Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 18, 2020
Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. SILVER SPRING, Md. ,
PLOS: DNA Science
MAY 16, 2024
A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. ” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013. .” But I think about that time often, and the warning that it sounded. Work on vaccines ensued too.
The Pharma Data
SEPTEMBER 8, 2020
is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. December 29, 2019. December 31, 2019. , For more information, visit. www.merck.com.
The Pharma Data
SEPTEMBER 8, 2020
About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. Forward-Looking Statement of Moderna, Inc.,
Codon
JULY 27, 2023
A LEGO robot , made by undergraduate students at Arizona State University, pours sucrose gradients (a tube with dense liquid at the bottom, and less dense liquid at the top), which are used to separate, say, proteins from RNA by spinning them really fast in centrifuges. How do transcription factors couple up with the correct RNA molecule?
Expert insights. Personalized for you.
130 
Let's personalize your content